Publications of Henry G Grabowski     :chronological  combined  bibtex listing:

Monographs

  1. "Patents and New Product Development in the Pharmaceuticals and Biotechnology Industries",  edited by John Duca Federal Reserve Bank of Dallas, 87-104. [PDF]
  2. The Search for New Vaccines: The Effects of the Vaccines for Children Program,  American Enterprise Institute for Public Policy Research: Washington, D.C., 1997.
  3. Health Care Cost Containment and Pharmaceutical Innovation,  Proceedings of the Conferences on Health Care and the Elderly, Washington, D.C., 1986 (25-28 pp.).
  4. The Regulation of Pharmaceuticals: Balancing the Benefits and Risks, with John Vernon, American Enterprise Institute for Public Policy Research: Washington, D.C., 1983.
  5. The Effects of Product Quality Regulation on Innovation in the U.S. Pharmaceutical Industry,  Final Report for the National Science Foundation Grant PRA 75-19823 (National Technical Information Services, Washington, D.C.), 1979.
  6. The Impact of Regulation on Industrial Innovation, with John Vernon, National Academy of Sciences: Washington, D.C., 1979.
  7. The Effects of Advertising on the Interindustry Distribution of Demand, Winter, 1976 (21-75 pp.).
  8. Drug Regulation and Innovation: Empirical Evidence and Policy Options,  American Enterprise Institute for Public Policy Research: Washington, D.C., 1976.

Journal Articles

  1. "Follow-on biologics: data exclusivity and the balance between innovation and competition," Nature Reviews Drug Discovery 7.6 (June, 2008): 479-488. [PDF]
  2. "Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act," with Y Richard Wang, Journal of Law and Economics  (Forthcoming 2008).
  3. "Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention," with Jeffrey L. Moe, Cancer Prevention Research  (2008). [PDF]
  4. "Should the Patent System for New Medicines Be Abolished," with JA DiMasi, Clinical Pharmacology & Therapeutics 82.5 (November, 2007): 488-491. [PDF]
  5. "Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention," with Jeffrey L. Moe, Duke Department of Economics Working Papers  (November, 2007). [PDF]
  6. "Entry and Competition in Generic Biologics," with David Ridley, and Kevin Schulman, Managerial and Decision Economics 28 (2007): 439-451. [PDF]
  7. "Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program," with Jennifer Li, Eric Eisenstein, Elizabeth Reid, Barry Mangum, Kevin Schulman, John Goldsmith, M Dianne Murphy, Robert Califf, and Daniel Benjamin, Jr., Journal of the American Medical Association 297.5 (2007): 480-488. [PDF]
  8. "The Economics of New Oncology Drug Development," with Joseph DiMasi, Journal of Clinical Oncology 25.2 (2007): 209-216. [PDF]
  9. "The Cost of Pharmaceutical R&D: Is Biotech Different?," with Joseph DiMasi, Managerial and Decision Economics 28 (2007): 469-479. [PDF]
  10. "Generic Competition and Market Exclusivity Periods in Pharmaceuticals," with Margaret Kyle, Managerial and Decision Economics 28 (2007): 491-502. [PDF]
  11. "How Did the 2003 Prescription Drug Re-Importation Bill Pass The House?," with Omar Gokcekus, Mike Adams, and Edward Tower, Economics & Politics 18.1 (March, 2006): 27-45. [PDF]
  12. "Generic Competition in the U.S. Pharmaceutical Industry," with Atanu Saha, Howard Birnbaum, Paul Greenberg, and Oded Bizan, International Journal of the Economics of Business  (February, 2006). Vol. 13, Issue 1, pp. 15-38 [PDF]
  13. "The Market for Follow-On Biologics: How Will It Evolve?," with Iain Cockburn, Genia Long, Health Affairs 25.5 (2006): 1291-1301. [PDF]
  14. "The Quantity and Quality of Worldwide New Drug Introductions 1992 - 2003," with Y. Richard Wang, Health Affairs 25.2 (2006): 452-460. [PDF]
  15. "Spending on Post-approval Drug Safety," with David Ridley, Judith Kramer, Hugh Tilson, and Kevin Schulman, Health Affairs 25.2 (2006): 429-436. [PDF]
  16. "Developing Drugs for Developing Countries," with David Ridley and Jeffrey Moe, Health Affairs 25.2 (2006): 313-324. [PDF]
  17. "Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act," H.G. Grabowski, Cambridge University Press Conference Volume  (2005): 457-480. [PDF] [abs]
  18. "Extraordinary Claims Require Extraordinary Evidence," with Joseph DiMasi and Ronald Hansen, Journal of Health Economics 24.5 (2005): 1034 - 1044. [PDF]
  19. "Setting the Record Straight on Setting the Record Straight: Response to Light and Warburton's Rejoiner," with Joseph DiMasi, Ronald Hansen, Journal of Health Economics 24.5 (2005): 1049. [PDF]
  20. "Encouraging the Development of New Vaccines," Health Affairs 24.3 (2005): 697-704. [PDF]
  21. "R&D Costs and Returns by Therapeutic Category," with Joseph DiMasi, and John Vernon, Drug Information Journal  (2004). [PDF]
  22. "Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures," PharmcoEconomics  (2004). [PDF] [abs]
  23. "The Ripple Effects of a Restrictive Medicaid Formulary (editorial)," American Journal of Managed Care 9.10 (October, 2003): 648-649. [PDF]
  24. "The Price of Innovation: New Estimates of Drug Development Costs," with Joseph DiMasi and Ronald Hansen, Journal of Health Economics 22 (2003): 141-185. [PDF]
  25. "Patents, Innovation and Access to New Pharmaceuticals," Journal of International Economic Law  (February, 2002): 849-860. Also presented at the American Association for the Advancement of Science, Annual Meetings, Boston [PDF]
  26. "Returns on R&D for 1990s New Drug Introductions," with John Vernon and Joe DiMasi, PharmacoEconomics 20.Supplement 3 (2002). [PDF]
  27. "The Determinants of Pharmaceutical Research and Development Expenditures," with John Vernon, Journal of Evolutionary Economics 10 (2000): 201-215. [PDF]
  28. "Effective Patent Life in Pharmaceuticals," with John Vernon, International Journal of Technology Management 19.1/2 (2000): 98-120. [PDF]
  29. "The Distribution of Sales Revenues from Pharmaceutical Innovation," with John Vernon, Pharmacoeconomics 18.suppl. 1 (2000): 21-32. [PDF]
  30. "The Role of Cost-Effectiveness Analysis in Managed Care Decisions," Pharmacoeconomics 14,suppl. 1 (1998): 15-24. [PDF]
  31. ""The Impact of Cost-Effectiveness on Public and Private Policies in Health Care: An International Perspective"," with Frank Sloan, Social Science & Medicine 45.4 (August, 1997). Edited Symposium Volume
  32. "Pharmacy, Benefit Management, Cost-Effectiveness Analysis and Drug Formulary Decisions," with Daniel C. Mullins, Social Science & Medicine 45.4 (August, 1997): 535-544. [PDF]
  33. "The Effect of Pharmacoeconomics on Company Research and Development Decisions," PharmacoEconomics 11.5 (May, 1997): 389-397.
  34. "Longer Patents for Increased Genetic Competition: The Waxman-Hatch Act After One Decade," PharmacoEconomics 10,Suppl. 2 (1996): 110-123. [PDF]
  35. "Research and Development Costs for New Drugs by Therapeutic Category: A Study of the U.S. Pharmaceutical Industry," with Joseph DiMasi, Ronald Hansen and Louis Lasagna, PharmacoEconomics 7.2 (1995): 152-169.
  36. "R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry," with Joseph A. DiMasi and John Vernon, International Journal of the Economics of Business 2.2 (1995): 201-219. Special volume honoring Merton J. Peck of Yale University [PDF]
  37. "Health Reform and Pharmaceutical Innovation," Seton Hall Law Review 24.3 (1994): 1221-1259. [PDF]
  38. "Innovation and Structural Change in Pharmaceuticals and Biotechnology," with John Vernon, Industrial and Corporate Change 3.2 (1994): 435-449. [PDF]
  39. "Returns to R&D on New Drug Introductions in the 1980s," H.G. Grabowski with John Vernon, Journal of Health Economics 13 (1994): 383-406. [PDF]
  40. "Brand Loyalty, Entry and Price Competition in Pharmaceuticals After the 1984 Drug Act," with John M. Vernon, Journal of Law and Economics 35.2 (October, 1992): 331-350. [PDF]
  41. "The Costs and Returns to Pharmaceutical Research and Development," Revista Internazionale di Scienze sociali (International Social Studies Review)  (September, 1992): 347-358.
  42. "The Effect of Medicaid Formularies on the Availability of New Drugs," with Stuart O. Schweitzer and S. Renee Shiota, PharmoEconomics 1(Suppl. 1) (1992): 32-40.
  43. "The Cost of Innovation in the Pharmaceutical Industry," with Joseph DiMasi, Ronald Hansen and Louis Lasagna, Johnal of Health Economics 10 (1991): 107-142.
  44. "A New Look at the Returns and Risks to Pharmaceutical R & D," with John Vernon, Management Science 36.7 (July, 1990): 804-821. [PDF]
  45. "Price and Availability Tradeoffs of Automobile Insurance Regulation," with W. Kip Viscusi and William N. Evans, Journal of Risk and Insurance LVI.2 (June, 1989): 275-299.
  46. "An Analysis of U.S. International Competitiveness in Pharmaceuticals," Managerial and Decision Economics, Special Issue  (1989): 27-33. [PDF]
  47. "Medicaid Patients' Access to New Drugs," Health Affairs  (Winter, 1988): 102-114.
  48. "Pioneers, Imitators, and Genetics--A Simulation Model of Schumpeterian Competition," with John Vernon, The Quarterly Journal of Economics  (August, 1987): 491-525.
  49. "The Health/Economic Benefits of Drug Therapy: Efficacy, Low Risk, Cost Effectiveness, Patient Information and Emancipation," Swiss Pharma 9.3a (1987): 29-31.
  50. "Longer Patents for Lower Imitation Barriers: The 1984 Drug Act," with John Vernon, The American Economic Review 76.2 (May, 1986): 195-198. [PDF]
  51. "Organizational Capital and the Choice between Specialization and Diversification," with Michael Gort and Robert McGuckin, Managerial and Decision Economics 6.1 (March, 1985): 2-10.
  52. "The Impact of Patent and Regulatory Policies on Drug Innovation," H.G. Grabowski, Medical Marketing & Media 18.10 (October, 1983): 42-63.
  53. "Automobile Safety Regulation: A Review of the Evidence," H.G. Grabowski with Richard J. Arnould, Research in Law and Economics 5 (1983): 233-267.
  54. "Public Policy and Pharmaceutical Innovation," Health Care Financing Review 4.1 (September, 1982): 75-87.
  55. "A Sensitivity Analysis of Expected Profitability of Pharmaceutical Research and Development," with John Vernon, Managerial and Decision Economics 3.1 (March, 1982): 36-40. [PDF]
  56. "Public Policy and Innovation: The Case of Pharmaceuticals," Technovation 1 (1982): 157-189.
  57. "Auto Safety Regulation: An Analysis of Market Failure," with Richard J. Arnould, The Bell Journal of Economics 12.1 (Spring, 1981): 27-48.
  58. "The Impact of Regulation on Innovation," Food Drug Cosmetic Law Journal 34.10 (October, 1979): 555-560.
  59. "Substitution Laws and Innovation in the Pharmaceutical Industry," with John Vernon, Law and Contemporary Problems  (Winter/Spring Issue 1979): 43-66. [PDF]
  60. "Industrial Research and Development, Intangible Capital Stocks, and Firm Profit Rates," with Dennis Mueller, Bell Journal of Economics 9.2 (Fall, 1978): 328-343.
  61. "The Effects of Advertising on IntraIndustry Shifts on Demand," Occasional Papers of the National Bureau of Economic Research, Explorations in Economic Research 4.5 (Fall, 1978): 675-701.
  62. "Consumer Product Safety Regulation," with John M. Vernon, American Economic Review 68 (May, 1978): 284-289.
  63. "Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry," with Vernon, John and Thomas, Lacy Glen, Journal of Law and Economics 21.1 (April, 1978): 133-163. [PDF]
  64. "Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry," with John M. Vernon and Lacy Glenn Thomas, Journal of Law and Economics 21.1 (April, 1978): 133-163.
  65. "Consumer Protection Regulation in Ethical Drugs," with John Vernon, American Economic Review 67.1 (February, 1977): 359-364. [PDF]
  66. "Life Cycle Effects on Corporate Returns on Retentions," with C. Dennis Mueller, Review of Economics and Statistics 57 (November, 1975): 400-409.
  67. "Rivalry in Research and Development: An Empirical Study," with Nevins D. Baxter, Journal of Industrial Economics 21.2 (July, 1973): 209-235.
  68. "Determinants and Distributional Aspects of Enrollment in U.S. Higher Education," with A. Corazzani and D. Dugan, Journal of Human Resources 7.1 (Winter, 1972): 39-59. [PDF]
  69. "Managerial and Stockholder Welfare Models of Firm Expenditures," with Dennis Mueller, Review of Economics and Statistics 54 (February, 1972): 9-24.
  70. "Imitative Advertising in the Cigarette Industry," with Dennis Mueller, The Journal of American and Foreign Antitrust and Trade Regulations 16.2 (Summer, 1971): 257-292.
  71. "Non-Price Competition in the Cigarette Industry: A Coment," with Dennis Mueller, Antitrust Bulletin 40 (Winter, 1970): 257-292.
  72. "Industrial Organization: The Role and Contribution of Econometrics," with Dennis Mueller, American Economic Review 60.2 (May, 1970): 100-104. [PDF]
  73. "Demand Shifting, Optimal Firm Growth, and Rule-of-Thumb Decision Making," Quarterly Journal of Econoics 84 (May, 1970): 217-235. [PDF]
  74. "The Determinents of Research and Development: A study of the chemical, drug, and petrolium industries," with Journal of Political Economy 76.2 (1968): 292-306. reprinted in K.S. Palda, ed., Readings in Managerial Economics, (Prentice-Hall), 1973; also reprinted in S. Yarney, ed., Economics of Industrial Structure: Selected Readings, (Penguine Modern Economics Series), 1973 [PDF]

Chapters in Books

  1. "Competition Between Generic and Branded Drugs," Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Anaysis in International Perspective, H.G. Grabowski. Edited by F. A. Sloan and C. T. Hsieh. 2007: 153-173. [PDF]
  2. "Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act," International Public Goods, and Transfer of Technology Under a Globalized Intellectual Property Regime, . Edited by Keith E. Maskus and Jerome H. Reichman. 2005: 457-480. Published by Cambridge University Press (Conference volume) [Pdf] [abs]
  3. "Patents and the Development of New Pharmaceuticals in Pharmaceuticals and Biotechnology Industry," Science and Cents: Exploring the Economics of Biotechnology, . Edited by Duca John V and Yucel, Mine K. April, 2002. Proceedings of the 2002 Conference on Exploring the Economics of Biotechnology [PDF]
  4. "Pressures from the Demand Side: Changing Market Dynamics and Industrial Structure," Consolidation and Competition in the Pharmaceutical Industry, with John Vernon. Edited by Hannah E. Kettler. 2001: 62-79.
  5. "Public Policy and Innovation in Pharmaceuticals and Biotechnology," Business and Economics for the 21st Century, Volume 1, . Edited by Demetri Kantarelis. 1997: 343-349.
  6. "Economic Scales and Tests," Quality of Life and Pharmacoeconomics in Clinical Trials, with Ronald W. Hansen. Edited by B. Spilker. Second Edition1996: 79-84.
  7. "Returns to Pharmaceutical R&D: Prospects Under Health Care Reform," Competitive Strategies in the Pharmaceutical Industry, with John Vernon. Edited by Robert Helms. 1996: 194-207.
  8. "Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol" Chapter 16," Psychopharmacology: The Fourth Generation of Progress, with Gary Zarkin, Josephine Mauskopf, Heather A. Bannerman, and Richard H. Weisler. Edited by Floyd E. Bloom and David J. Kupfer. 1995: 1897-1905.
  9. "Price and Profit Control, New Competitive Dynamics and the Economics of Innovation in the Pharmaceutical Industry," Industrial Policy and the Pharmaceutical Industry, . Edited by Adrian Towse. 1995: 77-91.
  10. "The Changing Economics of Pharmaceutical Research and Development," The Changing Economics of Medical Technology, H.G. Grabowski. Edited by Annetine C. Gelijns and Ethan A. Halm. 1991: 35-52.
  11. "Product Liability in the Pharmaceuticals: Comments on Chapters Eight and Nine," The Liability Maze: The Impact of Liability Law on Safety and Innovation, . Edited by Peter W. Huber and Robert E. Litan. 1991: 360-366.
  12. "Economic Scales and Tests," Quality of Life Assessments in Clinical Trials, with Ronald W. Hansen. Edited by B. Spilker. 1990: 61-69.
  13. "Innovation and International Competitiveness in Pharmaceuticals," Evolving Technology and Market Structure: Studies in Schumpeterian Economics, . Edited by Arnold Heertje and Mark Perlman. 1990: 167-185.
  14. "Economic Aspects of Vaccine Innovation and Manufacturing" Chapter," Vaccine Supply and Innovation, with Lawrence De Brock 1985: 45-64.
  15. "A Computer Simulation Model of Pharmaceutical Innovation," Pharmaceutical Economics, with John Vernon. Edited by Bjorn Lindgren. 1984: 159-175.
  16. "The Pharmaceutical Industry," Government and Technical Progress - A Cross-Industry Analysis, with John M. Vernon. Edited by Richard R. Nelson. 1982: 283-360.
  17. "An Evaluation of the Maximum Allowable Cost Program," The Effectiveness of Medicines in Containing Health Care Costs, with Jean P. Gagnon 1982: 81-113.
  18. "The Determinants of R&D Expenditures," Drugs and Health, with John Vernon. Edited by Robert B. Helms. 1981: 3-20.
  19. "Regulation and Industrial Innovation," Industrial Innovation and Public Policy Options: Background Papers for a Colloquium,  1981: 65-81.
  20. "Regulation and the International Diffusion of Pharmaceuticals," The International Supply of Medicines, . Edited by Robert B. Helms. 1980: 5-36.
  21. "New Studies on Market Definition, Concentration, Theory of Supply, Entry and Promotion," Issues in Pharmaceutical Economics, with John M. Vernon. Edited by Robert I. Chien. 1979: 29-52.
  22. "Regulation of the United States Pharmaceutical Industry: Current Problems and Policy Developments," Medicines for the Year 2000, . Edited by George Teeling-Smith. 1979: 57-74.
  23. "Structural Effects of Regulation on Innovation in the Ethical Drug Industry" (Chapter 10," Essays on Industrial Organization in Honor of Joe S. Bain, with John Vernon. Edited by Robert T. Masson and P. David Qualls. 1976: 181-205.
  24. "The Effects of Regulatory Policy on the Incentives to Innovate: An International Comparative Analysis," Impact of Public Policy on Drug Innovation and Pricing, with John Vernon and Lacy Glenn Thomas. Edited by Emery A. Link and Samuel Mitchell. 1976: 47-93.
  25. "Advertising and Resource Allocation: A Critique," Advertising and the Public Interest, . Edited by Salvatore F. Davita. 1974.
  26. "A Graph-Oriented Model for Research Management," Research Program Effectiveness, with Oscar Morgenstern and R.W. Shepherd. Edited by M.C. Yovits, D.M. Gilford, E. Staveley and H.D. Lerner. 1966: 187-216.

Other

  1. "Returns to Pharmaceutical R&D in the 1990s," (July, 2001). Tufts University Conference, Center for the Study of Drug Development, Talloires France
  2. "Patent Policy Issues in Pharmaceuticals," (March, 2001). Robert Wood Johnson Foundation Colloquium on the Pharmaceutical Industry, Washington, D.C.
  3. "New Research on the Returns to Pharmaceutical R & D," (October, 2000). American Enterprise Institute, Washington, D.C.
  4. "The Distribution of Sales Revenues from Pharmaceutical Innovation," (June, 2000). Schumpeterian Society Meetings, Manchester, England
  5. ""Effective Patent Life in Pharmaceuticals"," (June, 1999). U.S. House of Representatives Colloquium for House Staff Members
  6. "Health Reform and Pharmaceutical Innovation," (1994). American Enterprise Institute for Public Policy Research, Washington, D.C.
  7. "Pharmaceuticals and Health Care Costs," (October, 1993). International Health Care Forum, "Health Care Policy and the Pharmaceutical Industry," Gotemba, Japan [PDF]
  8. "Pharmaceutical Research and Development: Return and Risk," (1991). Sixth Annual Centre for Medicines Research Lecture, Centre for Medicine Research, Surrey, England
  9. "Impact of Patent and Regulatory Policies on Drug Innovation," Proceedings of the Second Annual Shearson Lehman Hutton Conference on Legal and Regulatory Issues Affecting Biotechnology and Health Care (October, 1988): 5-16.
  10. "Studies on Drug Substitution, Patent Policy and Innovation in the Pharmaceutical Industry," (1985). Final report to the National Science Foundation available from the National Technical Information Services, Number PB-85-109700, Washington, D.C.